Latest Articles

Publication Date
All News Scientific
Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer - Oncodaily

Giuseppe Caruso: KEYTRUDA Improves Progression-Free Survival in Frontline dMMR Endometrial Cancer Oncodaily

Published: July 16, 2026, 4:40 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Read Full Article
Dostarlimab Boosts Long-Term Survival in Endometrial Cancer - Medscape

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer Medscape

Published: June 22, 2026, 1 p.m.
Read Full Article
Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer - OncLive

Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer OncLive

Published: June 17, 2026, 9:31 p.m.
Read Full Article
PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer - Medscape Reference

PD-1 Inhibitors Improve Survival for dMMR Endometrial Cancer Medscape Reference

Published: June 17, 2026, 2:51 p.m.
Read Full Article
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post

Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post

Published: June 3, 2026, 2:49 p.m.
Read Full Article
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily

NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily

Published: June 3, 2026, 3:15 a.m.
Read Full Article
Pancreatic cancer breakthrough: New daily pill nearly doubles survival time in advanced patients - TheHealthSite

Pancreatic cancer breakthrough: New daily pill nearly doubles survival time in advanced patients TheHealthSite

Published: June 2, 2026, 10:11 a.m.
Read Full Article
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN

Published: June 2, 2026, 12:41 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!